The market has been feeling a lot like déjà vu in a variety of ways. And we’re not just talking about the current banking crisis or last year’s tech meltdown. There are some big positives as well. And one of them happens to be in the healthcare sector.
For the major pharmaceuticals and biotech drug developers, it’s beginning to feel a lot like the go-go days of the late 90s. Pipelines are fat, new blockbusters have hit the market, M&A is rising, and spin-offs are creating growth opportunities. It’s feeling good for investors too. Dividends and buybacks are starting to surge.
With that in mind, the major drug developers and the funds that track them could be worth a portfolio look for income seekers. The sector hasn’t been this good in years.
Get Premium to keep reading
This is a premium article. Please login to your Dividend.com Premium account to access this article.
Login Now
